av/cymabay-therapeutics--big.svg

NASDAQ:CBAY

CymaBay Therapeutics Inc

  • Stock

32.48

+0.03%

0.01

USD last updated 11/08 02:03:55

Last Close

32.47

21/03 20:00

Market Cap

3.73B

Beta: 0.26

Volume Today

8.35M

Avg: 1.67M

PE Ratio

−23.78

PFCF: −42.19

OverviewFinancialsAPI

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

This will be loaded shortly.

Loading

This is also still loading.

    Description

    CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), a...Show More

    Excel Tearsheet

    Earnings

    Earnings per Share (Estimate*)

    -0.4-0.3-0.2-0.12017-03-232018-08-092019-12-312021-11-102023-05-15

    Revenue (Estimate*)

    5M10M15M20M25M30M35M2017-03-232018-08-092019-12-312021-11-102023-05-15

    *Estimate based on analyst consensus